Evidence map›Paper›PMID 24729086›Full record

SynthesisTumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine2014

The association between the GSTP1 A313G and GSTM1 null/present polymorphisms and the treatment response of the platinum-based chemotherapy in non-small cell lung cancer (NSCLC) patients: a meta-analysis.

Yanlong Yang, Lei Xian

Abstract readMeta-Analysis
PubMed Publisher
In one paragraph

Synthesis in Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 6 pooled it
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 6 syntheses or guidelines pooled it, 26 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. GSTT1 and GSTM1 polymorphisms predict treatment outcome for breast cancer: a systematic review and meta-analysis.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016
    Pooled it
  6. Pooled it
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Oncotarget · 2017
    Article
  16. Article
  17. Article
  18. Article
  19. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Yanlong YangDepartment of Cardiothoracic Surgery, the First Affiliated Hospital of Guangxi Medical University, Nanning, 530021, Guangxi Zhuang Autonomous Region, China, yangyl58@163.com.
Lei Xian
First Affiliated Hospital of GuangXi Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The relationship between the GSTP1 A313G and GSTM1 null/present polymorphisms and the treatment response (TR) of platinum-based chemotherapy in non-small cell lung cancer (NSCLC) patients have been extensively investigated by many studies, but the results were inconsistent and inconclusive. The aim of this meta-analysis was to further explore the predictive value of the GSTP1 and GSTM1 polymorphisms by collecting currently available evidence. Relevant studies were searched in PubMed, Embase, and CNKI. Inclusion criteria were NSCLC patients receiving platinum-based treatment, evaluated GSTP1 A313G or GSTM1 null/present polymorphisms, and TR. Odds ratio (OR) with 95 % confidence interval (CI) was calculated to assess the strength of the associations. Subgroup analysis by race was also conducted to explore the source of heterogeneity. A total of nine studies including 961 NSCLC patients were qualified for analysis. We found that GSTM1 null/present but not GSTP1 A313G polymorphism was associated with platinum-based TR (for GSTM1, null vs present: OR = 1.77, 95% CI = 1.19-2.62). When subgroup analysis by race was done, both GSTP1 and GSTM1 polymorphisms were significantly associated with TR in East-Asian patients, but not in Caucasians. In addition, the heterogeneity disappeared in Asian and Caucasian patients when subgroup analysis by race was done. Our study suggested that the GSTP1 A313G and GSTM1 null/present polymorphisms could predict the treatment response of the platinum-based chemotherapy in NSCLC patients, especially in East-Asian patients.

Indexed as

Asian PeopleBiomarkers, PharmacologicalCarcinoma, Non-Small-Cell LungGenetic Predisposition to DiseaseGlutathione S-Transferase piGlutathione TransferaseHumansPlatinumPolymorphism, Single NucleotideBiomarkers, PharmacologicalGlutathione S-Transferase piGlutathione TransferasePlatinum

Identifiers

PMID24729086
OpenAlexW1998725041

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.